Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Acronyms PASCAL401
  • Sponsors Kowa
  • Most Recent Events

    • 18 Jun 2019 According to a Kowa Pharmaceuticals America media release, the approval of LIVALO (pitavastatin) for pediatric patients was granted in conjunction with fulfillment of FDAs Written Request to obtain pediatric information on pitavastatin and provides a 6-month pediatric exclusivity with regard to the U.S. patent protection for LIVALO.
    • 18 Jun 2019 According to a Kowa Pharmaceuticals America media release, the pediatric label indication for LIVALO is supported by a 12-week, double-blind, placebo-controlled trial (n=82, pediatric patients 8 to 16 years of age with heterozygous familial hypercholesterolemia (HeFH), EudraCT2011-004964-32), and a 52-week open-label trial (n=85, pediatric patients with HeFH, EudraCT2011-004983-32).
    • 18 Jun 2019 According to a Kowa Pharmaceuticals America media release, the U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering drug LIVALO (pitavastatin) for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top